Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Darunavir/Cobicistat FDC vs Separate Agents in Healthy Participants
NCT04718805Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of darunavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Analyte Concentration of Darunavir at 72 hours, Area Under the Analyte Concentration-time Curve from time Zero to Last Quantifiable time of Darunavir at 72 hours and 1 more. Started Jan 2021; status: completed.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04718805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718805.